

Inder S Anand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7807288/publications.pdf>

Version: 2024-02-01

343
papers

38,162
citations

2963

93
h-index

3257

185
g-index

346
all docs

346
docs citations

346
times ranked

23373
citing authors

#	ARTICLE	IF	CITATIONS
1	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1995-2008.	13.9	4,108
2	Spironolactone for Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2014, 370, 1383-1392.	13.9	1,993
3	The Seattle Heart Failure Model. <i>Circulation</i> , 2006, 113, 1424-1433.	1.6	1,744
4	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2019, 381, 1609-1620.	13.9	1,485
5	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. <i>European Heart Journal</i> , 2010, 31, 703-711.	1.0	797
6	Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT). <i>Circulation</i> , 2003, 107, 1278-1283.	1.6	786
7	Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. <i>Circulation</i> , 2015, 131, 34-42.	1.6	758
8	Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure. <i>Circulation</i> , 2007, 116, 1242-1249.	1.6	635
9	Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2062-2076.	1.2	467
10	Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2013, 368, 1210-1219.	13.9	462
11	Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2017, 135, e1054-e1091.	1.6	417
12	Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2016, 37, 455-462.	1.0	396
13	C-Reactive Protein in Heart Failure. <i>Circulation</i> , 2005, 112, 1428-1434.	1.6	393
14	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	13.9	381
15	Anemia and Its Relationship to Clinical Outcome in Heart Failure. <i>Circulation</i> , 2004, 110, 149-154.	1.6	371
16	Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation</i> , 2015, 132, 402-414.	1.6	371
17	Anemia and Iron Deficiency in Heart Failure. <i>Circulation</i> , 2018, 138, 80-98.	1.6	352
18	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	3.8	340

#	ARTICLE	IF	CITATIONS
19	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
20	Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. <i>Journal of the American College of Cardiology</i> , 2002, 40, 1414-1421.	1.2	331
21	The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. <i>European Heart Journal</i> , 2004, 25, 292-299.	1.0	319
22	Direct Comparison of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP in a Large Population of Patients with Chronic and Symptomatic Heart Failure: The Valsartan Heart Failure (Val-HeFT) Data. <i>Clinical Chemistry</i> , 2006, 52, 1528-1538.	1.5	317
23	Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2004, 364, 347-354.	6.3	315
24	Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.2	301
25	Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction. <i>Circulation</i> , 2010, 121, 1393-1405.	1.6	290
26	Autonomic Regulation Therapy via Left or Right Cervical Vagus Nerve Stimulation in Patients With Chronic Heart Failure: Results of the ANTHEM-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 808-816.	0.7	289
27	Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 104-115.	1.6	288
28	Effect of the Calcium Antagonist Felodipine as Supplementary Vasodilator Therapy in Patients With Chronic Heart Failure Treated With Enalapril. <i>Circulation</i> , 1997, 96, 856-863.	1.6	287
29	Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 2454-2458.	1.6	279
30	Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure. <i>Circulation</i> , 2010, 122, 1387-1395.	1.6	272
31	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	2.9	264
32	Prediction of Mode of Death in Heart Failure. <i>Circulation</i> , 2007, 116, 392-398.	1.6	261
33	Anemia and Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 501-511.	1.2	253
34	2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart		

#	ARTICLE	IF	CITATIONS
37	Anemia and Change in Hemoglobin Over Time Related to Mortality and Morbidity in Patients With Chronic Heart Failure. <i>Circulation</i> , 2005, 112, 1121-1127.	1.6	243
38	Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 324-331.	1.6	238
39	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 471-482.	1.9	238
40	Prognostic Relevance of Left Atrial Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, e002763.	1.6	224
41	Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics. <i>Journal of Physiology</i> , 2016, 594, 3911-3954.	1.3	222
42	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 326-336.	1.6	222
43	Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 569-577.	1.6	219
44	Cardiac Structure and Function and Prognosis in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 740-751.	1.6	218
45	Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure. <i>Circulation</i> , 2012, 125, 280-288.	1.6	209
46	Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2022-2027.	1.2	206
47	Evaluation of the effects of sodium-glucose cotransporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1279-1287.	2.9	205
48	Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. <i>European Journal of Heart Failure</i> , 2015, 17, 925-935.	2.9	203
49	Mode of Death in Advanced Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 2329-2334.	1.2	202
50	Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. <i>Circulation</i> , 2009, 120, 835-842.	1.6	202
51	Augmented Short- and Long-Term Hemodynamic and Hormonal Effects of an Angiotensin Receptor Blocker Added to Angiotensin Converting Enzyme Inhibitor Therapy in Patients With Heart Failure. <i>Circulation</i> , 1999, 99, 2658-2664.	1.6	198
52	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021, 144, 1284-1294.	1.6	195
53	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	1.6	193
54	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1406-1416.	0.4	188

#	ARTICLE	IF	CITATIONS
55	Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. <i>European Journal of Heart Failure</i> , 2016, 18, 1193-1202.	2.9	180
56	Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 571-578.	1.6	177
57	Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin. <i>Circulation: Heart Failure</i> , 2011, 4, 613-620.	1.6	165
58	Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients With Advanced Heart Failure. <i>Circulation</i> , 2009, 119, 969-977.	1.6	159
59	Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. <i>Lancet, The</i> , 2019, 394, 1254-1263.	6.3	159
60	Aquapheresis Versus Intravenous Diuretics and Hospitalizations for Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 95-105.	1.9	158
61	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. <i>Circulation</i> , 2018, 137, 286-297.	1.6	157
62	Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients With Severe Heart Failure Treated With a Mineralocorticoid Receptor Antagonist. <i>Circulation: Heart Failure</i> , 2014, 7, 573-579.	1.6	155
63	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	2.9	155
64	Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial. <i>Circulation: Heart Failure</i> , 2013, 6, 184-192.	1.6	154
65	Copeptin Helps in the Early Detection of Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 150-160.	1.2	153
66	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2017, 135, 724-735.	1.6	153
67	Effect of Left Ventricular Scar Size, Location, and Transmurality on Left Ventricular Remodeling With Healed Myocardial Infarction. <i>American Journal of Cardiology</i> , 2007, 99, 1109-1114.	0.7	144
68	Regional and ethnic differences among patients with heart failure in Asia: the Asian sudden cardiac death in heart failure registry. <i>European Heart Journal</i> , 2016, 37, 3141-3153.	1.0	144
69	Surrogate end points in heart failure. <i>Journal of the American College of Cardiology</i> , 2002, 39, 1414-1421.	1.2	142
70	Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. <i>European Journal of Heart Failure</i> , 2013, 15, 511-518.	2.9	140
71	Long-Term caspase inhibition ameliorates apoptosis, reduces myocardial troponin-I cleavage, protects left ventricular function, and attenuates remodeling in rats with myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004, 43, 295-301.	1.2	135
72	Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 241-252.	1.9	129

#	ARTICLE	IF	CITATIONS
73	Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1057-1067.	1.2	128
74	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054.	1.6	128
75	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2017, 5, 280-286.	1.9	127
76	sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2309-2320.	1.2	126
77	Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2014, 7, 418-426.	1.6	123
78	Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 278-286.	2.9	122
79	Anemia in Patients With Heart Failure: Prevalence and Prognostic Role in a Controlled Trial and in Clinical Practice. <i>Journal of Cardiac Failure</i> , 2005, 11, 91-98.	0.7	118
80	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1416-1420.	0.4	118
81	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
82	Proteinuria, Chronic Kidney Disease, and the Effect of an Angiotensin Receptor Blocker in Addition to an Angiotensin-Converting Enzyme Inhibitor in Patients With Moderate to Severe Heart Failure. <i>Circulation</i> , 2009, 120, 1577-1584.	1.6	116
83	A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 73-84.	1.9	115
84	Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. <i>The Lancet Global Health</i> , 2018, 6, e1008-e1018.	2.9	113
85	Relationships Between Clinical Assessments and Patients' Perceptions of the Effects of Heart Failure on Their Quality of Life. <i>Journal of Cardiac Failure</i> , 2006, 12, 87-92.	0.7	112
86	Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. <i>European Journal of Heart Failure</i> , 2009, 11, 795-801.	2.9	107
87	Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients. <i>JACC: Heart Failure</i> , 2013, 1, 192-199.	1.9	107
88	Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). <i>Contributions To Nephrology</i> , 2010, 165, 54-67.	1.1	106
89	DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure. <i>Circulation</i> , 2009, 119, 3093-3100.	1.6	104
90	Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI and Val-HeFT trials. <i>European Journal of Heart Failure</i> , 2015, 17, 424-433.	2.9	104

#	ARTICLE	IF	CITATIONS
91	Calculated plasma volume status and prognosis in chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 35-43.	2.9	104
92	Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. <i>Journal of the American College of Cardiology</i> , 1995, 25, 1402-1407.	1.2	102
93	Heart failure with preserved ejection fraction in Asia. <i>European Journal of Heart Failure</i> , 2019, 21, 23-36.	2.9	102
94	Isolated Myocyte Contractile Function Is Normal in Postinfarct Remodeled Rat Heart With Systolic Dysfunction. <i>Circulation</i> , 1997, 96, 3974-3984.	1.6	102
95	Ventricular remodeling in heart failure: a credible surrogate endpoint. <i>Journal of Cardiac Failure</i> , 2003, 9, 350-353.	0.7	97
96	Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 601-612.	1.2	97
97	Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. <i>PLoS Medicine</i> , 2018, 15, e1002541.	3.9	97
98	Incremental Prognostic Value of Changes in B-Type Natriuretic Peptide in Heart Failure. <i>American Journal of Medicine</i> , 2006, 119, 70.e23-70.e30.	0.6	95
99	Effect of dialysis and renal transplantation on autonomic dysfunction in chronic renal failure. <i>Kidney International</i> , 1991, 40, 489-495.	2.6	94
100	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	2.9	93
101	Sustained Reduction of Aldosterone in Response to the Angiotensin Receptor Blocker Valsartan in Patients With Chronic Heart Failure. <i>Circulation</i> , 2003, 108, 1306-1309.	1.6	91
102	Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2011, 4, 561-568.	1.6	91
103	Effects of Inhaled Nitric Oxide and Oxygen in High-Altitude Pulmonary Edema. <i>Circulation</i> , 1998, 98, 2441-2445.	1.6	90
104	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	1.0	90
105	Extended Follow-Up of Patients With Heart Failure Receiving Autonomic Regulation Therapy in the ANTHEM-HF Study. <i>Journal of Cardiac Failure</i> , 2016, 22, 639-642.	0.7	88
106	Heart Failure With Improved Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	86
107	High output cardiac failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2001, 3, 151-159.	0.4	80
108	Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2007, 13, 797-804.	0.7	80

#	ARTICLE	IF	CITATIONS
109	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (lâ€Preserve). <i>European Journal of Heart Failure</i> , 2014, 16, 778-787.	2.9	80
110	Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	80
111	Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardiac Resynchronisation Therapy. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2606-2618.	1.2	79
112	Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. <i>Cardiovascular Drugs and Therapy</i> , 1998, 12, 291-299.	1.3	78
113	Asian Sudden Cardiac Death in Heart Failure (ASIANâ€HF) registry. <i>European Journal of Heart Failure</i> , 2013, 15, 928-936.	2.9	78
114	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006539.	1.6	78
115	A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. <i>Heart Rhythm</i> , 2015, 12, 2069-2077.	0.3	77
116	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77
117	Cardiac Resynchronization Therapy in Patients With Minimal Heart Failure. <i>Journal of the American College of Cardiology</i> , 2011, 58, 935-941.	1.2	74
118	Sacubitrilâ€valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. <i>European Heart Journal</i> , 2021, 42, 3741-3752.	1.0	74
119	Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. <i>American Journal of Cardiology</i> , 1991, 67, 732-736.	0.7	73
120	Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. <i>European Journal of Heart Failure</i> , 2007, 9, 397-402.	2.9	72
121	The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 429-441.	1.9	72
122	Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone. <i>Circulation: Heart Failure</i> , 2015, 8, 1052-1058.	1.6	70
123	Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2019, 8, e013114.	1.6	69
124	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 689-697.	1.9	68
125	Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 664-675.	1.9	68
126	Worsening Renal Function and Outcome in Heart Failure Patients With Preserved Ejection Fraction and the Impact of Angiotensin Receptor Blocker Treatment. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1106-1113.	1.2	67

#	ARTICLE	IF	CITATIONS
127	Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. <i>International Journal of Cardiology</i> , 2007, 119, 48-53.	0.8	66
128	Important Differences in Mode of Death Between Men and Women With Heart Failure Who Would Qualify for a Primary Prevention Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2012, 126, 2402-2407.	1.6	66
129	Chronic heart failure with preserved left ventricular ejection fraction: Diagnostic and prognostic value of left atrial size. <i>International Journal of Cardiology</i> , 2006, 110, 386-392.	0.8	65
130	Isosorbide Dinitrate and Hydralazine in a Fixed-Dose Combination Produces Further Regression of Left Ventricular Remodeling in a Well-Treated Black Population With Heart Failure: Results From A-HeFT. <i>Journal of Cardiac Failure</i> , 2007, 13, 331-339.	0.7	65
131	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 39.	3.8	65
132	Short-term Mortality Risk in Emergency Department Acute Heart Failure. <i>Academic Emergency Medicine</i> , 2011, 18, 947-958.	0.8	64
133	A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2014, 16, 1175-1182.	2.9	64
134	Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. <i>PLoS Medicine</i> , 2019, 16, e1002916.	3.9	64
135	Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 217-225.	1.6	63
136	Heart failure and anemia: mechanisms and pathophysiology. <i>Heart Failure Reviews</i> , 2008, 13, 379-386.	1.7	62
137	Elevated Plasma Renin Activity Predicts Adverse Outcome in Chronic Heart Failure, Independently of Pharmacologic Therapy: Data From the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2010, 16, 964-970.	0.7	62
138	The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT). <i>Journal of Cardiac Failure</i> , 2006, 12, 375-380.	0.7	61
139	Influence of Blood Pressure on the Effectiveness of a Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine in the African-American Heart Failure Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 32-39.	1.2	60
140	Active infective endocarditis observed in an Indian hospital 1981-1991. <i>American Journal of Cardiology</i> , 1992, 70, 1453-1458.	0.7	59
141	Incidence of Appropriate Shock in Implantable Cardioverter-Defibrillator Patients With Improved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2013, 19, 426-430.	0.7	59
142	Autonomic Regulation Therapy for the Improvement of Left Ventricular Function and Heart Failure Symptoms: The ANTHEM-HF Study. <i>Journal of Cardiac Failure</i> , 2013, 19, 655-660.	0.7	59
143	Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study. <i>European Journal of Heart Failure</i> , 2018, 20, 491-500.	2.9	59
144	Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 26.	3.0	59

#	ARTICLE	IF	CITATIONS
145	Design and Performance of a Multisensor Heart Failure Monitoring Algorithm: Results From the Multisensor Monitoring in Congestive Heart Failure (MUSIC) Study. <i>Journal of Cardiac Failure</i> , 2012, 18, 289-295.	0.7	57
146	Sudden Cardiac Death in Heart Failure Patients With Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2012, 18, 749-754.	0.7	57
147	Effect of dapagliflozin on anaemia in <scp>DAPAâ€HF</scp>. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	2.9	57
148	Sudden Death in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 653-661.	1.9	56
149	Regional Variation of Mortality in Heart Failure With Reduced and Preserved Ejection Fraction Across Asia: Outcomes in the ASIANâ€CHF Registry. <i>Journal of the American Heart Association</i> , 2020, 9, e012199.	1.6	55
150	Combinatorial Pharmacogenetic Interactions of Bucindolol and Î²1, Î±2C Adrenergic Receptor Polymorphisms. <i>PLoS ONE</i> , 2012, 7, e44324.	1.1	55
151	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	1.9	53
152	Changes in Nâ€terminal proâ€Bâ€type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the Iâ€Preserve study. <i>European Journal of Heart Failure</i> , 2015, 17, 809-817.	2.9	52
153	Heart Failure With Preserved Ejection Fraction in the Young. <i>Circulation</i> , 2018, 138, 2763-2773.	1.6	52
154	Microvascular Disease in Patients With Diabetes With Heart Failure and Reduced Ejection Versus Preserved Ejection Fraction. <i>Diabetes Care</i> , 2019, 42, 1792-1799.	4.3	52
155	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 974-984.	2.9	52
156	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	1.6	51
157	Noninvasive assessment of left ventricular remodeling: Concepts, techniques, and implications for clinical trials. <i>Journal of Cardiac Failure</i> , 2002, 8, S452-S464.	0.7	48
158	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	2.9	47
159	Biomarkers in kidney and heart disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 62-74.	0.4	46
160	Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. <i>European Journal of Heart Failure</i> , 2012, 14, 22-31.	2.9	46
161	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.	1.2	46
162	Role of brain natriuretic peptide in the diagnosis and management of heart failure: Current concepts. <i>Journal of Cardiac Failure</i> , 2002, 8, 288-299.	0.7	45

#	ARTICLE	IF	CITATIONS
163	Syndromes of Subacute Mountain Sickness. <i>High Altitude Medicine and Biology</i> , 2004, 5, 156-170.	0.5	45
164	Meta-Analysis of Combined Therapy with Angiotensin Receptor Antagonists versus ACE Inhibitors Alone in Patients with Heart Failure. <i>PLoS ONE</i> , 2010, 5, e9946.	1.1	43
165	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. <i>JACC: Heart Failure</i> , 2013, 1, 338-344.	1.9	43
166	Cardiac Troponin I and Risk of Cardiac Events in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005312.	1.6	43
167	Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2000-2007.	1.2	42
168	Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: REDâ€HF study. <i>European Journal of Heart Failure</i> , 2018, 20, 268-277.	2.9	42
169	Relationship of Quality of Life Scores With Baseline Characteristics and Outcomes in the African-American Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, 835-842.	0.7	41
170	Pathophysiology of Anemia in Heart Failure. <i>Heart Failure Clinics</i> , 2010, 6, 279-288.	1.0	41
171	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2018, 3, 1000.	3.0	41
172	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEMâ€HF, INOVATEâ€HF, and NECTARâ€HF. <i>ESC Heart Failure</i> , 2020, 7, 76-84.	1.4	41
173	Plasma MMP-2, MMP-9 and N-BNP in Long-Term Survivors Following Complicated Myocardial Infarction: Relation to Cardiac Magnetic Resonance Imaging Measures of Left Ventricular Structure and Function. <i>Journal of Cardiac Failure</i> , 2007, 13, 843-849.	0.7	40
174	Effect of Baseline and Changes in Systolic Blood Pressure Over Time on the Effectiveness of Valsartan in the Valsartan Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2008, 1, 34-42.	1.6	40
175	Digoxin Use and Heart Failure Outcomes: Results from the Valsartan Heart Failure Trial (Valâ€HeFT). <i>Congestive Heart Failure</i> , 2010, 16, 191-195.	2.0	38
176	QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 477-486.	1.9	38
177	Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	38
178	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	1.2	38
179	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2015, 17, 169-176.	2.9	36
180	Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIANâ€HF registry. <i>European Journal of Heart Failure</i> , 2019, 21, 297-307.	2.9	36

#	ARTICLE	IF	CITATIONS
181	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.	1.6	35
182	Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease. <i>European Journal of Heart Failure</i> , 2015, 17, 1201-1207.	2.9	35
183	Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2017, 23, 20-28.	0.7	35
184	Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2018, 11, e005288.	1.6	35
185	Incidence and Outcomes of Pneumonia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	1.2	35
186	Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1043-1052.	2.9	34
187	Cardiovascular and hormonal effects of calcitonin gene-related peptide in congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1991, 17, 208-217.	1.2	33
188	Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 970-976.	1.6	33
189	Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. <i>European Journal of Heart Failure</i> , 2013, 15, 324-333.	2.9	33
190	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 2093-2101.	2.9	33
191	Prospective Evaluation of Elastic Restraint to Lessen the Effects of Heart Failure (PEERLESS-HF) Trial. <i>Journal of Cardiac Failure</i> , 2012, 18, 446-458.	0.7	32
192	Cardiorenal Syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1800-1807.	2.2	32
193	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. <i>International Journal of Cardiology</i> , 2019, 277, 166-172.	0.8	32
194	The role of arginine vasopressin and its receptors in the normal and failing rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2003, 35, 495-504.	0.9	31
195	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1777-1784.	0.4	31
196	Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. <i>American Heart Journal</i> , 2017, 191, 75-81.	1.2	31
197	Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HF study. <i>ESC Heart Failure</i> , 2018, 5, 95-100.	1.4	31
198	Racial Differences in Characteristics and Outcomes of Patients With Heart Failure and Preserved Ejection Fraction in the Treatment of Preserved Cardiac Function Heart Failure Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004457.	1.6	31

#	ARTICLE	IF	CITATIONS
199	Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. <i>Circulation</i> , 2020, 142, 1532-1544.	1.6	31
200	Long-term Follow-Up of Patients with Heart Failure and Reduced Ejection Fraction Receiving Autonomic Regulation Therapy in the ANTHEM-HF Pilot Study. <i>International Journal of Cardiology</i> , 2021, 323, 175-178.	0.8	31
201	Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 497-509.	2.9	30
202	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 1247-1258.	2.9	29
203	Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β -Blocker Evaluation of Survival Trial [BEST]). <i>American Heart Journal</i> , 2010, 160, 649-654.	1.2	28
204	Design of the Multi-Sensor Monitoring in Congestive Heart Failure (MUSIC) Study: Prospective Trial to Assess the Utility of Continuous Wireless Physiologic Monitoring in Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 11-16.	0.7	28
205	Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2018, 20, 483-490.	2.9	28
206	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1751-1759.	0.8	28
207	Cardiomyocytes from hearts with left ventricular dysfunction after ischemia-reperfusion do not manifest contractile abnormalities. <i>Journal of the American College of Cardiology</i> , 1999, 34, 594-602.	1.2	27
208	Heart Failure Risk Prediction Models. <i>JACC: Heart Failure</i> , 2014, 2, 437-439.	1.9	26
209	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T. <i>European Journal of Heart Failure</i> , 2020, 22, 2078-2088.	2.9	26
210	Pulse Pressure, Prognosis, and Influence of Sacubitril/Valsartan in Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 546-556.	1.3	26
211	Mechanisms and management of renal dysfunction in heart failure. <i>Current Opinion in Cardiology</i> , 1997, 12, 251-258.	0.8	25
212	Global Differences in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e007901.	1.6	25
213	Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. <i>International Journal of Cardiology</i> , 1990, 28, 341-346.	0.8	24
214	Myocyte Response to β -Adrenergic Stimulation Is Preserved in the Noninfarcted Myocardium of Globally Dysfunctional Rat Hearts After Myocardial Infarction. <i>Circulation</i> , 2000, 102, 1840-1846.	1.6	24
215	Validation of a Risk Score for Dying Within 1 Year of an Admission for Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, 276-280.	0.7	24
216	Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). <i>European Journal of Heart Failure</i> , 2013, 15, 334-341.	2.9	24

#	ARTICLE	IF	CITATIONS
217	Use of Isosorbide Dinitrate and Hydralazine in African-Americans With Heart Failure 9 Years After the African-American Heart Failure Trial. <i>American Journal of Cardiology</i> , 2014, 114, 151-159.	0.7	24
218	Effects of combined renin-angiotensin-aldosterone system inhibitor and beta-blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from <scp>BIOSTAT-CHF</scp> and <scp>ASIAN-CHF</scp> registries. <i>European Journal of Heart Failure</i> , 2020, 22, 1472-1482.	2.9	24
219	Ventricular Preexcitation Modulates Strain and Attenuates Cardiac Remodeling in a Swine Model of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 1162-1169.	1.6	23
220	Trend in prevalence of coronary artery disease and risk factors over two decades in rural Punjab. <i>Heart Asia</i> , 2017, 9, e010938.	1.1	23
221	Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-CHF registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1281-1289.	2.9	23
222	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. <i>Circulation: Heart Failure</i> , 2015, 8, 717-724.	1.6	22
223	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. <i>JACC: Heart Failure</i> , 2019, 7, 586-598.	1.9	22
224	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 478-486.	1.9	21
225	Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 782-791.	1.9	21
226	Prevalence, clinical correlates, and outcomes of anaemia in multi-ethnic Asian patients with heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2018, 5, 570-578.	1.4	21
227	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	1.6	21
228	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. <i>Circulation: Heart Failure</i> , 2019, 12, e005766.	1.6	21
229	Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin+ Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study). <i>American Journal of Cardiology</i> , 2019, 123, 611-617.	0.7	21
230	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 418-427.	1.9	20
231	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. <i>Clinical Research in Cardiology</i> , 2021, 110, 1280-1291.	1.5	20
232	NT-proBNP for Risk Prediction in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 653-663.	1.9	20
233	Balloon dilatation of double-chamber right ventricle. <i>American Heart Journal</i> , 1990, 120, 1234-1236.	1.2	19
234	Lack of pain during myocardial infarction in diabetics - Is autonomic dysfunction responsible?. <i>American Journal of Cardiology</i> , 1991, 68, 793-796.	0.7	19

#	ARTICLE	IF	CITATIONS
235	Antistreptokinase antibodies before and after streptokinase therapy in patients with acute myocardial infarction from areas endemic for streptococcal infection and influence on reperfusion rates. <i>American Journal of Cardiology</i> , 1994, 74, 187-189.	0.7	19
236	Improvement of left ventricular diastolic function and left atrial reverse remodeling after catheter ablation of premature ventricular complexes. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 38, 179-185.	0.6	19
237	Profile of right-sided endocarditis: an Indian experience. <i>International Journal of Cardiology</i> , 1991, 33, 83-88.	0.8	18
238	Ventricular remodeling without cellular contractile dysfunction. <i>Journal of Cardiac Failure</i> , 2002, 8, S401-S408.	0.7	18
239	Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation. <i>American Heart Journal</i> , 2015, 170, 1099-1104.	1.2	18
240	Application of the H ₂ FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	2.9	18
241	Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008293.	1.6	18
242	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. <i>Circulation</i> , 2022, 145, 158-169.	1.6	18
243	Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 336-346.	1.9	18
244	Traditional and Novel Approaches to Management of Heart Failure: Successes and Failures. <i>Cardiology Clinics</i> , 2008, 26, 59-72.	0.9	17
245	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (PRESERVE) trial. <i>European Journal of Heart Failure</i> , 2016, 18, 1021-1031.	2.9	17
246	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
247	Effect of Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine on All Hospitalizations and on 30-Day Readmission Rates in Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 759-765.	1.6	16
248	Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 303-309.	0.7	16
249	An Update on Cardiac Troponins as Circulating Biomarkers in Heart Failure. <i>Current Heart Failure Reports</i> , 2010, 7, 15-21.	1.3	15
250	Telephone Titration of Heart Failure Medications. <i>Journal of Cardiovascular Nursing</i> , 2011, 26, 29-36.	0.6	15
251	Utility of natriuretic peptides to assess and manage patients with heart failure receiving angiotensin receptor blocker/nephrilysin inhibitor therapy. <i>Postgraduate Medicine</i> , 2018, 130, 299-307.	0.9	15
252	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e022069.	1.6	15

#	ARTICLE	IF	CITATIONS
253	Circulating levels and prognostic cutoffs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure. <i>ESC Heart Failure</i> , 2022, 9, 2084-2095.	1.4	15
254	Critical stenosis of aortic and mitral valves after mediastinal irradiation. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 247-250.	0.7	14
255	Factors affecting seasonal changes in blood pressure in North India: A population based four-seasons study. <i>Indian Heart Journal</i> , 2018, 70, 360-367.	0.2	14
256	How I treat anemia in heart failure. <i>Blood</i> , 2020, 136, 790-800.	0.6	14
257	Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. <i>American Journal of Cardiology</i> , 2005, 95, 558-564.	0.7	13
258	Carvedilol Versus Controlled-Release Metoprolol for Elderly Veterans with Heart Failure. <i>Journal of the American Geriatrics Society</i> , 2008, 56, 1021-1027.	1.3	13
259	High-Output Heart Failure Revisited —. <i>Journal of the American College of Cardiology</i> , 2016, 68, 483-486.	1.2	13
260	Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure). <i>Circulation: Heart Failure</i> , 2018, 11, e004431.	1.6	13
261	Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008052.	1.6	13
262	Socioeconomic Status and Outcomes in Heart Failure With Reduced Ejection Fraction From Asia. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006962.	0.9	13
263	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
264	Monitoring Changes in Fluid Status With a Wireless Multisensor Monitor: Results From the Fluid Removal During Adherent Renal Monitoring (FARM) Study. <i>Congestive Heart Failure</i> , 2012, 18, 32-36.	2.0	12
265	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. <i>Emergency Medicine Journal</i> , 2013, 30, 633-637.	0.4	12
266	Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 333-345.	1.0	12
267	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006638.	1.6	12
268	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 776-784.	2.9	12
269	Chronic obstructive pulmonary disease and β -blocker treatment in Asian patients with heart failure. <i>ESC Heart Failure</i> , 2018, 5, 297-305.	1.4	11
270	Burden of Heart Failure Signs and Symptoms, Prognosis, and Response to Therapy. <i>JACC: Heart Failure</i> , 2021, 9, 386-397.	1.9	11

#	ARTICLE	IF	CITATIONS
271	Effects of A 1 Adenosine Receptor Agonism Using N 6 -Cyclohexyl-2â€²- O -Methyladenosine in Patients With Left Ventricular Dysfunction. <i>Circulation</i> , 1996, 94, 1212-1215.	1.6	11
272	Atrial Fibrillation Following Electrical Injury.. <i>International Heart Journal</i> , 1992, 33, 131-134.	0.6	10
273	Pathogenesis of Anemia in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 699-700.	1.6	10
274	Midregional Proadrenomedullin Predicts Mortality and Major Adverse Cardiac Events in Patients Presenting With Chest Pain: Results From the <scp>CHOPIN</scp> Trial. <i>Academic Emergency Medicine</i> , 2015, 22, 554-563.	0.8	10
275	Swallowing induced supraventricular ectopics in a patient with straight back syndrome.. <i>International Heart Journal</i> , 1989, 30, 523-526.	0.6	9
276	Serial sampling of copeptin levels improves diagnosis and risk stratification in patients presenting with chest pain: results from the CHOPIN trial. <i>Emergency Medicine Journal</i> , 2016, 33, 23-29.	0.4	9
277	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	1.2	9
278	Patientâ€reported outcomes in heart failure with preserved vs. reduced ejection fraction: focus on physical independence. <i>ESC Heart Failure</i> , 2020, 7, 2051-2062.	1.4	9
279	Developing and validating models to predict sudden death and pump failure death in patients with heart failure and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2021, 110, 1234-1248.	1.5	8
280	Cardiac Resynchronization Therapy in the Real World: Comparison With the COMPANION Study. <i>Journal of Cardiac Failure</i> , 2012, 18, 153-158.	0.7	7
281	Biomarkers. <i>Heart Failure Clinics</i> , 2012, 8, 207-224.	1.0	7
282	Iron Deficiency in Heart Failure. <i>Cardiology</i> , 2014, 128, 317-319.	0.6	7
283	Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. <i>European Journal of Heart Failure</i> , 2022, 24, 861-866.	2.9	7
284	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 87-95.	2.0	6
285	Clinical Trial Report: Reevaluating Telemonitoring in Heart Failure. <i>Current Heart Failure Reports</i> , 2011, 8, 84-86.	1.3	6
286	Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. <i>Advances in Therapy</i> , 2017, 34, 1976-1988.	1.3	6
287	Post-Extrasystolic Potentiation asâ€Predictor of Recovery of Leftâ€Ventricularâ€Dysfunction After Radiofrequency Catheter Ablation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1283-1291.	1.3	6
288	T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF. <i>Clinical Research in Cardiology</i> , 2019, 108, 133-141.	1.5	6

#	ARTICLE	IF	CITATIONS
289	Copeptin to rule out myocardial infarction in Blacks versus Caucasians. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 395-403.	0.4	6
290	Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies. <i>ESC Heart Failure</i> , 2019, 6, 1052-1056.	1.4	6
291	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6
292	Ethnic differences in atrial fibrillation among patients with heart failure in Asia. <i>ESC Heart Failure</i> , 2020, 7, 1419-1429.	1.4	6
293	Readmissions, Death and Its Associated Predictors in Heart Failure With Preserved Versus Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021414.	1.6	6
294	Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. <i>Vascular Health and Risk Management</i> , 2010, 6, 449-55.	1.0	6
295	Pathogenesis of anemia in cardiorenal disease. <i>Reviews in Cardiovascular Medicine</i> , 2005, 6 Suppl 3, S13-21.	0.5	6
296	Predicting survival in heart failure. <i>Current Cardiology Reports</i> , 2007, 9, 209-217.	1.3	5
297	Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: Rationale and design. <i>American Heart Journal</i> , 2012, 164, 638-645.	1.2	5
298	ENCORE: Extension of the ANTHEM-HF Study Evaluating Autonomic Regulation Therapy in Reduced Ejection Fraction Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 940.	0.7	5
299	Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. <i>European Journal of Heart Failure</i> , 2019, 21, 685-688.	2.9	5
300	Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2020, 22, 557-559.	2.9	5
301	Baseline NT-proBNP and responsiveness to autonomic regulation therapy in patients with heart failure and reduced ejection fraction. <i>IJC Heart and Vasculature</i> , 2020, 29, 100520.	0.6	5
302	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the <i>ADRB1</i> Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009591.	2.1	5
303	Letter from the Siachen Glacier. <i>High Altitude Medicine and Biology</i> , 2001, 2, 553-557.	0.5	4
304	Is too much neurohormonal blockade harmful?. <i>Current Cardiology Reports</i> , 2004, 6, 169-175.	1.3	4
305	Research Needed to Support Clinical Use of Biomarkers as Prognostic Indicators for Patients with Heart Failure. <i>Cardiology Research and Practice</i> , 2010, 2010, 1-6.	0.5	4
306	Troponin T and Plasma Collagen Peptides in Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 394-397.	1.6	4

#	ARTICLE	IF	CITATIONS
307	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. <i>Biomarkers</i> , 2012, 17, 490-497.	0.9	4
308	Impact of renal dysfunction on the Seattle Heart Failure Model. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 163-169.	0.3	4
309	Potassium abnormalities in patients with heart failure from 11 Asian regions: insights from the ASIAN-HF registry. <i>European Journal of Heart Failure</i> , 2020, 22, 751-754.	2.9	4
310	Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 754-758.	2.9	4
311	Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients. <i>American Heart Journal</i> , 2020, 222, 93-104.	1.2	4
312	Utilization of propionyl-L-carnitine for the treatment of heart failure. <i>Developments in Cardiovascular Medicine</i> , 1995, , 323-335.	0.1	4
313	Prevalence and Prognostic Significance of Frailty in Asian Patients With Heart Failure. <i>JACC Asia</i> , 2021, 1, 303-313.	0.5	4
314	Rate-dependent hemodynamic responses during incremental atrial pacing in chronic before and after surgery. <i>American Journal of Cardiology</i> , 1993, 72, 615-619.	0.7	3
315	The Heart Failure Society of America in 2020: A Vision for the Future. <i>Journal of Cardiac Failure</i> , 2012, 18, 90-93.	0.7	3
316	The Post-Myocardial Infarction Pacing Remodeling Prevention Therapy (PRomPT) Trial: Design and Rationale. <i>Journal of Cardiac Failure</i> , 2015, 21, 601-607.	0.7	3
317	Necessity of hospitalization and stress testing in low risk chest pain patients. <i>American Journal of Emergency Medicine</i> , 2017, 35, 274-280.	0.7	3
318	Electroanatomic Ratios and Mortality in Patients With Heart Failure: Insights from the ASIAN-HF Registry. <i>Journal of the American Heart Association</i> , 2021, 10, e017932.	1.6	3
319	Introduction: anemia in heart failure. <i>Heart Failure Reviews</i> , 2008, 13, 377-378.	1.7	2
320	Autonomic Regulation Therapy Titration Methodology Accelerates Adaptation to Low-Intensity Vagus Nerve Stimulation. <i>Journal of Cardiac Failure</i> , 2014, 20, S71.	0.7	2
321	Response by Anand and Gupta to Letter Regarding Article, "Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies". <i>Circulation</i> , 2018, 138, 2976-2977.	1.6	2
322	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>JACC Asia</i> , 2022, , .	0.5	2
323	Survival Probability and Survival Benefit Associated With Primary Prevention Implantable Cardioverter-Defibrillator Generator Changes. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	2
324	Balloon Dilation of Postoperative Persistent Coarctation of Aorta and Valvular Aortic Stenosis—A Case Report. <i>Angiology</i> , 1992, 43, 614-617.	0.8	1

#	ARTICLE	IF	CITATIONS
325	Fixed-Dose Combination of Isosorbide Dinitrate and Hydralazine Inhibits Left Ventricular Remodeling in Well-Treated Severe Heart Failure in African-Americans: A-HeFT. <i>Journal of Cardiac Failure</i> , 2005, 11, 720.	0.7	1
326	Alterations in Ventricular Structure. , 2011, , 232-253.		1
327	What Explains the Benefits of ARNI Therapy in Heart Failure?. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1285-1287.	1.2	1
328	The biological variation of plasma proenkephalin: data from a stable heart failure cohort. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e105-e107.	1.4	1
329	Therapeutic responsiveness to vagus nerve stimulation in patients receiving beta-blockade for heart failure with reduced ejection fraction. <i>IJC Heart and Vasculature</i> , 2021, 37, 100888.	0.6	1
330	Persistent Autonomic Engagement and Cardiac Control After Four or More Years of Autonomic Regulation Therapy Using Vagus Nerve Stimulation. <i>Frontiers in Physiology</i> , 2022, 13, 853617.	1.3	1
331	Circulating levels and prognostic cut-offs of sST2, high-sensitivity troponin T, and NT-proBNP in women vs. men with chronic heart failure. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	1
332	Cost of antihypertensive treatment: A point of view from India. <i>Cardiovascular Drugs and Therapy</i> , 1989, 3, 761-765.	1.3	0
333	Creatine kinase-MB release during pacing-induced transient myocardial ischemia. <i>Coronary Artery Disease</i> , 1992, 3, 61-66.	0.3	0
334	Aldosterone in syndromes of untreated congestive heart failure. <i>Journal of the American College of Cardiology</i> , 1996, 27, 338-339.	1.2	0
335	Ventricular Pre-Excitation Acutely Modulates Mechanical Loading Characteristics Following Myocardial Infarction in a Swine Model. <i>Journal of Cardiac Failure</i> , 2006, 12, S22.	0.7	0
336	Worsening Renal Function in Acute Decompensated Congestive Heart Failure: A Function of Intrinsic Renal Disease or Hemodynamic Alteration with Heart Failure Treatment?. <i>Journal of Cardiac Failure</i> , 2007, 13, S171.	0.7	0
337	Corrigendum to "Design of the Reduction of Events with Darbeoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial" [Eur J Heart Fail 2009;11:795-801]. <i>European Journal of Heart Failure</i> , 2010, 12, 765-765.	2.9	0
338	Response to Letter Regarding Article, "DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study" <i>Circulation</i> , 2010, 121, .	1.6	0
339	Is Chronic Severe Anemia an Independent Predictor of Poor Outcomes?. <i>Cardiology</i> , 2011, 120, 89-90.	0.6	0
340	Heart Failure with Recovered Ejection Fraction: Clinical Characteristics, Correlates of Recovery, and Survival. Results from Val-HeFT. <i>Journal of Cardiac Failure</i> , 2016, 22, S47.	0.7	0
341	Plasma norepinephrine and atrial natriuretic peptide in heart failure: Influence of felodipine in the third vasodilator heart failure trial. <i>Journal of Cardiac Failure</i> , 2000, 6, 97-107.	0.7	0
342	Structural Remodeling in the Development of Chronic Systolic Heart Failure: Implication for Treatment. , 2017, , 247-265.		0

#	ARTICLE	IF	CITATIONS
343	Dose Limiting, Adverse Event Associated Bradycardia with β -blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. Heart Rhythm O2, 2021, 3, 40-49.	0.6	0